Initial Response and Outcome of Critically Ill Children With Guillain Barre' Syndrome.

Front Pediatr

Department of Pediatrics, Kasr Alainy Faculty of Medicine, Cairo University, Cairo, Egypt.

Published: September 2019

Guillain-Barre syndrome is the most common cause of acute flaccid paralysis worldwide since the eradication of poliomyelitis. Severe cases may require intensive care and mechanical ventilation. was to study pediatric patients with severe GBS requiring intensive care unit (ICU) admission, to assess their course and response to initial treatment modality plasma exchange (PE) or intravenous immunoglobulins (IVIg) and their final outcome. children with severe GBS who had either actual or impending respiratory failure, bulbar involvement or rapid progression of acute flaccid paralysis with trunk, upper limb and neck involvement within 24 h of the onset of weakness were enrolled. 40 children were included. Following the initial treatment (33 subjects had 5 PE sessions each and IVIg in 7), 16 patients improved (40%), two died and 22 (55%) showed initial treatment failure. Axonal neuropathy, rapid progression and severe motor weakness significantly predicted poor response to therapy. At discharge, favorable outcomes (patient can walk unaided) were present in 22 cases (58%). Despite relatively low mortality, critically ill children with severe GBS have increased prevalence of axonal neuropathy and guarded response to initial therapy with PE or IVIg.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6759753PMC
http://dx.doi.org/10.3389/fped.2019.00378DOI Listing

Publication Analysis

Top Keywords

severe gbs
12
initial treatment
12
critically ill
8
ill children
8
acute flaccid
8
flaccid paralysis
8
intensive care
8
response initial
8
children severe
8
rapid progression
8

Similar Publications

Maternal and neonatal outcomes of Group B Streptococcus colonization: a retrospective study.

BMC Infect Dis

January 2025

Department of Obstetrics and Gynecology, Taixing People's Hospital, No.1, Changzheng Road, Taixing, Jiangsu, 225400, China.

Background: Group B Streptococcus (GBS) colonization is one of the major causes of severe neonatal infections. The study was intended to identify GBS colonization in pregnant women, explore its potential risk factors, and analyze the impact of GBS on outcomes for both mothers and newborns.

Material And Methods: A retrospective research was carried out on pregnant women who had undergone GBS screening and delivered from June 2020 to December 2022.

View Article and Find Full Text PDF

Coronavirus disease (COVID-19) is a disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that primarily affects the respiratory system but can also lead to neurological complications such as Guillain-Barré syndrome (GBS). This case report describes an eight-year-old boy with COVID-19-associated GBS involving multiple cranial nerves (third, seventh, and ninth) without pulmonary symptoms. The patient initially presented with flu-like symptoms along with right facial paralysis, which progressed to bilateral facial paralysis, limb weakness, and sensory loss.

View Article and Find Full Text PDF

Background: Group B Streptococcus (GBS) is the most common cause of neonatal early onset sepsis in term infants and a major cause of late onset sepsis in both term and preterm infants.

Aim: To estimate the incidence of GBSS among neonates born in Qatar between July 2015 and June 2020 (5 years). A secondary aim was to describe the outcomes of the affected babies.

View Article and Find Full Text PDF

Background: This study aimed to investigate the risk factors associated with the severity of the disease, the need for mechanical ventilation (MV) and poor prognosis in the early stages of Guillain-Barré Syndrome (GBS).

Methods: Data of children who met GBS diagnostic criteria were evaluated retrospectively. The sample was divided into three binary subgroups according to severe GBS (Hughes Functional Grading Scale [HFGS] ≥ 4 at admission), mechanical ventilation (MV) requirement, and poor prognosis (inability to walk independently, HFGS ≥ 3 after six months).

View Article and Find Full Text PDF

The recent landscape of RSV vaccine research.

Ther Adv Vaccines Immunother

January 2025

Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, OX1 2JD, UK.

Respiratory syncytial virus (RSV) causes a significant burden of acute respiratory illness across all ages, particularly for infants and older adults. Infants, especially those born prematurely or with underlying health conditions, face a high risk of severe RSV-related lower respiratory tract infections (LRTIs). Globally, RSV contributes to millions of LRTI cases annually, with a disproportionate burden in low- and middle-income countries (LMICs).

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!